For decades, the idea of replacing the brain cells lost in Parkinson's disease has been one of medicine's great unfinished projects. Today some of the most advanced attempts to make it real are taking place in China, and they are attracting surprisingly little attention outside the country.
Four Chinese stem cell programmes for Parkinson's are now treating patients. The leading candidate has just finished enrolling a 30 patient phase II trial and has been granted Fast Track status by the US Food and Drug Administration. Here is what the results show so far, and how China compares with the better known Western efforts.
Why replacing dopamine cells matters
Parkinson's disease is driven by the gradual loss of dopamine producing neurons deep in the brain. Today's medicines, such as levodopa, top up dopamine but cannot replace the cells themselves. Over time they work less predictably, leaving patients with long "OFF" periods when tremor, stiffness and slowness return.
Cell replacement aims to fix the problem at its source. Scientists grow new dopamine cells from stem cells in the laboratory and transplant them into the putamen, the part of the brain that has lost its dopamine supply. If the cells survive and connect, they can produce dopamine naturally for years.
XS411: an off the shelf cell therapy from XellSmart
The front runner is XS411, developed by Chinese company XellSmart. It is made from induced pluripotent stem cells (iPSCs), adult cells reprogrammed into a stem cell state, which are then turned into dopamine neural progenitors. Crucially, it is allogeneic and off the shelf: the same cell product can be given to any patient without matching tissue types, which makes it far easier to manufacture and deliver at scale than therapies made from each patient's own cells.
Phase I results: five more hours of good time each day
The phase I trial treated nine people with moderate to advanced Parkinson's, on average around ten years after diagnosis and at Hoehn and Yahr stage 3 to 4 when off medication. Each received a single transplant into both sides of the putamen. Six months later, the results were striking:
Patients gained on average more than five hours a day of good "ON" time, when their symptoms are well controlled. Their motor scores while off medication (MDS-UPDRS Part III) improved by more than 30 points. 18F-DOPA PET scans showed increased tracer uptake, consistent with the transplanted cells surviving and making dopamine. Just as importantly, there were no serious adverse events, no dose limiting side effects, no graft induced dyskinesias (the uncontrolled movements that troubled earlier fetal cell transplants), and no abnormal cell growth on repeated MRI scans.
Nine patients is a small group, and phase I is designed mainly to test safety. But gains of this size are rarely seen in Parkinson's trials, and they explain why the programme has moved forward so quickly.
A 30 patient phase II trial is now fully enrolled
In July 2026 XellSmart completed enrolment of a 30 patient phase II trial led by Beijing Tiantan Hospital, working with Peking Union Medical College Hospital, Soochow University and Jiangsu Province Hospital. The trial uses a PROBE design, in which the doctors assessing patients' movement do not know which treatment they received, a step towards the kind of evidence regulators need for approval.
The same month, the FDA granted XS411 Fast Track designation, and a parallel US phase I trial is under way. In China the programme is backed by the National Major Innovative Drug Program. Results were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS) in October 2026.
Three more Chinese programmes in the clinic
XS411 is not alone. UX-DA001 from YueSai Bio uses each patient's own iPSC derived cells and is in a phase I trial at Ruijin Hospital in Shanghai. Its first patient was treated in March 2025, with reports of substantial functional recovery after one year in early cases.
NouvNeu001 from iRegene is another off the shelf iPSC dopamine therapy in a phase I/II trial in China. It already holds an FDA investigational new drug clearance along with Fast Track and Regenerative Medicine Advanced Therapy designations, and the company is developing a second candidate, NouvNeu003, for early onset Parkinson's.
NCR201 from Zhongsheng Suyuan is in a phase I trial that uses robot assisted surgery to place the cells precisely, at a university hospital in Hefei.
All four treatments are delivered the same way: living cells are placed directly into the putamen through stereotactic brain surgery. They cannot be taken as a pill or an injection into the bloodstream.
How China compares with the West
In Western coverage, the stem cell story for Parkinson's is usually told through two programmes. STEM-PD, run by Lund University and the University of Cambridge, is an early phase 1/2 study with eight patients. BlueRock Therapeutics, owned by Bayer, has moved its therapy bemdaneprocel into a phase III trial, mainly in the United States, Canada and Australia.
BlueRock is the furthest along in formal trial stage. But China now has more iPSC Parkinson's programmes treating patients than any other country, and XS411's phase II is larger than the European study and already uses blinded assessment. It is striking how rarely these Chinese trials appear in Western reporting, given that one of them now holds an FDA Fast Track designation and another has received both Fast Track and RMAT status from the same agency.
When could patients get access?
If phase III trials confirm the early results, an optimistic timeline would see the leading Chinese candidates approved by China's National Medical Products Administration in 2029 or 2030. No applications have yet been made to European regulators such as Swissmedic or the UK's MHRA, so availability in Europe is likely to come later, from around 2031.
Larger trials and longer follow up will decide how durable these benefits are. What is already clear is that China has moved from following to leading in one of the most hopeful areas of Parkinson's research, and OrientSciences will follow these programmes as results are published.